Yi Liu, Ph.D.
Chief Executive Officer

Yi Liu, Ph.D., is a co-founder of Kumquat Biosciences and served as Chief Executive Officer since November, 2018.  Previously, Dr. Liu served as Chief Scientific Officer of Wellspring Biosciences Inc. until July, 2019, a private biopharmaceutical company he co-founded in July 2012.  From October 2014 to November 2018, Dr. Liu served as Chief Scientific Officer of Kura Oncology, a public company he co-founded in August 2014. Dr. Liu also co-founded Intellikine, Inc., a private biopharmaceutical company, where he served as Vice President of Drug Discovery from 2007 to May 2012, until its acquisition by Takeda Pharmaceuticals. Prior to Intellikine, Dr. Liu was the head of the drug design group at the Genomics Institute of the Novartis Research Foundation. Earlier in his career, he held senior scientist positions at both SGX Pharmaceuticals, Inc., and Curagen Corporation. Dr. Liu received his Ph.D. in Biochemistry from Princeton University, his M.Sc. in computational chemistry from Beijing University and his B.E. in Chemical Engineering from Tsinghua University.

Lynn Yang, Sequoia Capital China

Lynn Yang, focusing on healthcare investment. Prior to joining Sequoia Capital China in May,2015, Lynn worked at healthcare team of Legend Capital. Lynn accomplished investment deals in different area of healthcare industry such as Burning Rock, Cstone(2616.HK), JW Therapeutics, Grail, Hongkong Asia Medical, Qihan Bio (eGenesis counterpart in China), Hifibio etc. Before setting her foot in venture capital, Lynn worked as business development manager in Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds a MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Carl Gordon, OrbiMed

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. For the last five years (2014 to 2018) Forbes® Magazine named Mr. Gordon one of the top 100 venture capitalists in the world when it placed him on the “Forbes Midas List”. Carl received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (1993) and a Bachelor of Arts Degree from Harvard College (1987).

Board Observers

Gavin Xia, LAV

Gavin G. Xia, Ph.D., is a Principal with Lilly Asia Ventures (LAV). Prior to joining LAV, Gavin was with Navigant Consulting and Monitor Group in healthcare business consulting industry and has served clients in pharmaceutical, medical device, and chemical industries in both US and Asia markets across projects ranging from M&A to market entry strategy to geographic expansion. Prior to consulting, Gavin had over more than 10 years academic and industry research experience in drug discovery and development. Gavin received his Ph.D. degree in Chemistry from University of Chicago in 2007, and his dual Bachelor’s in Chemistry and Economics from Peking University in 2001.

Scott Platshon, EcoR1

Scott Platshon joined Kumquat Biosciences as a Board Observer in August 2019. Since 2015, he has served as a principal at EcoR1 Capital, a fundamental biotechnology-focused investment firm in San Francisco. Prior to that, he was an analyst for Aquilo Partners, a boutique life-science investment bank. Scott holds a Bachelor of Science in Bioengineering from Stanford University.

Mitchell Mutz, RVF

Mitchell Mutz, PhD, is a Senior Investment Director at the Roche Venture Fund, a $500M evergreen fund, and is based at Genentech in South San Francisco. He serves on the boards of Pandion Therapeutics, Good Therapeutics, Purigen Biosystems, and is a board observer for Kumquat Biosciences and Fabric Genomics. He joined the Roche Venture Fund in 2017, bringing a broad depth of experience as founder, President, and Chief Scientific Officer of Amplyx Pharmaceuticals, a clinical stage therapeutics company that is currently developing APX001, a novel, broad spectrum antifungal compound. He is also an inventor on 35 issued patents. Dr. Mutz also helped start Labcyte, Inc, a tools company that uses acoustic beams to achieve precise, non-contact transfer of liquid without the use of pipet tips.  Labcyte has received widespread industry recognition including selection by the World Economic Forum as a 2015 Technology Pioneer, has over 220 employees worldwide, and has seen their technology adopted by all top ten major pharmaceutical companies. Labcyte was acquired by Beckman Coulter Life Sciences in 2019. Dr. Mutz received his PhD in Chemistry from the University of Rochester, NY, his Diploma in Orchestral Studies from the University of London, England, and a BA in Chemistry from Oberlin College.

Scientific Advisors

Kevan Shokat, Chairman of SAB
Investigator, Howard Hughes Medical Institute

Professor and Vice-Chair, Department of Cellular and Molecular Pharmacology
University of California, San Francisco

Kevan’s laboratory is focused on the discovery of new small molecule tools and drug candidates targeting protein/lipid kinases, GTPases, and RNA helicases. His lab utilizes the tools of synthetic organic chemistry, protein engineering, structural biology, biochemistry and cell biology. In oncology and neurodegenerative diseases he focuses primarily on targets in pathways which have been validated by human genetics such as the lipid kinase PIK3CA mutants (20% of human tumors), the most frequently mutated human oncogene—the GTPase–KRAS, the metabolic and growth factor sensitive kinase mTOR, the mitochondrial kinase, PINK1 (Parkinson’s Disease), the kinase Lrrk2 (Parkinson’s Disease). Kevan is currently an Investigator of the Howard Hughes Medical Institute, vice-chair of the Department of Cellular and Molecular Pharmacology at the University of California at San Francisco, and Professor in the Department of Chemistry at the University of California at Berkeley.  He received his B.A. in Chemistry from Reed College in 1986.  After receiving his Ph.D. in organic chemistry at UC Berkeley with Professor Peter Schultz, and post-doctoral work in cellular immunology at Stanford University with Professor Chris Goodnow, he began his independent research career at Princeton University before moving to UCSF in 1999. He was inducted into the National Academy of Sciences (2010), the Institute of Medicine (2011), and the American Academy of Arts and Sciences (2011).  He has commercialized discoveries from his laboratory through co-founding several biotechnology companies including, Cellular Genomics, Intellikine, Araxes, Kura, eFFECTOR, Revolution Medicines and Mitokinin.